respiratori
pathogen
panel
nxtag
rpp
ivdclear
assay
simultan
detect
identif
nucleic
acid
respiratori
virus
outsid
us
atyp
bacteri
pathogen
nasopharyng
swab
scalabl
allow
concurr
test
sampl
singl
batch
nucleic
acid
extract
raw
specimen
use
extractor
ad
directli
preplat
lyophil
bead
reagent
lbr
multiplex
rtpcr
hybrid
microspher
occur
within
seal
reaction
well
use
singl
cycl
program
data
acquisit
done
instrument
read
sort
reaction
product
directli
seal
well
follow
transfer
assay
plate
thermal
cycler
nxtag
newest
innov
beadbas
nucleic
acid
chemistri
develop
luminex
provid
detail
assay
protocol
present
data
describ
clinic
analyt
perform
characterist
nxtag
rpp
respiratori
tract
infect
rti
involv
wide
varieti
etiolog
agent
present
overlap
sign
symptom
therefor
predict
caus
organ
base
clinic
find
alon
reliabl
among
variou
diagnost
test
avail
multiplex
nucleic
acid
amplif
assay
capabl
detect
identifi
multipl
respiratori
pathogen
commonli
use
clinic
microbiolog
laboratori
respiratori
viral
panel
rvp
first
multiplex
molecular
assay
respiratori
pathogen
clear
vitro
diagnost
use
capabl
detect
common
respiratori
virus
subtyp
depend
geograph
region
xtag
rvp
incorpor
multiplex
revers
transcript
pcr
rtpcr
multiplex
target
specif
primer
extens
tspe
luminex
xtag
technolog
proprietari
univers
sequenc
tag
sort
system
allow
easi
develop
optim
nucleic
acid
assay
microspher
assay
system
sampl
spike
intern
control
subject
nucleic
acid
extract
nucleic
acid
extract
subject
multiplex
rtpcr
treat
shrimp
alkalin
phosphatas
exonucleas
exo
inactiv
remain
nucleotid
degrad
leftov
primer
multiplex
tspe
use
detect
label
viral
nucleic
acid
amplifi
pcr
incorpor
uniqu
sequenc
tag
extens
time
introduct
major
innov
revolution
approach
diagnosi
respiratori
infect
much
faster
tradit
cultur
immunolog
test
entir
xtag
rvp
procedur
still
take
approxim
h
complet
addit
open
platform
system
potenti
risk
crosscontamin
specimen
extract
pcr
amplif
step
subsequ
luminex
develop
xtag
fast
assay
chemistri
employ
tag
primer
label
primer
togeth
targetspecif
multiplex
rtpcr
assay
order
streamlin
workflow
shorten
time
result
approxim
h
fast
version
assay
incorpor
origin
nonmagnet
xtag
microspher
wherea
version
assay
detect
magnet
magplextag
microspher
follow
nucleic
acid
extract
multiplex
rtpcr
reaction
aliquot
amplifi
tag
target
simultan
hybrid
xtag
magplextag
microspher
label
report
dye
detect
either
analyz
format
elimin
postpcr
cleanup
tspe
step
workflow
entir
decreas
time
result
h
reduc
tube
openingtransf
step
one
xtag
rvp
fast
andor
xtag
rvp
fast
ivdclear
target
depend
geograph
region
newest
gener
univers
tag
sort
chemistri
luminex
respiratori
pathogen
panel
rpp
launch
decemb
nxtag
rpp
incorpor
multiplex
rtpcr
univers
tag
system
form
lyophil
reagent
provid
close
system
amplif
detect
respiratori
viral
bacteri
target
pcr
bead
hybrid
compon
includ
tag
primer
fluorescentlylabel
primer
enzym
dntp
buffer
magplextag
microspher
combin
precis
mixtur
lyophil
small
bead
lyophil
bead
reagent
lbr
lbr
preplat
individu
well
plate
allow
scalabl
batch
test
reaction
extract
total
nucleic
acid
ad
preplat
lbr
seal
individu
reaction
well
pierc
pipett
tip
foil
seal
reaction
mix
pipett
resuspend
reaction
compon
reseal
fresh
foil
seal
reaction
amplifi
via
rtpcr
reaction
product
undergo
near
simultan
bead
hybrid
within
singl
seal
reaction
well
open
procedur
need
nucleic
acid
extract
amplif
therebi
virtual
elimin
risk
carryov
contamin
hybrid
tag
bead
sort
read
instrument
signal
analyz
use
nxtag
rpp
assay
file
softwar
provid
qualit
call
target
intern
control
within
reaction
well
note
standard
precaut
taken
regard
sampl
collect
handl
storag
prior
extract
refer
clsi
farka
et
al
specimen
extern
control
extract
use
system
specimen
store
day
collect
univers
transport
media
equival
specimen
go
test
within
day
collect
may
store
month
follow
institut
clsi
guidelin
appropri
run
qc
control
note
pierc
foil
sure
touch
black
adhes
reseal
plate
sampl
addit
use
precut
strip
foil
provid
appli
foil
directli
top
plate
press
firmli
around
well
ensur
tight
seal
ensur
foil
cover
well
surround
black
adhes
vortex
spin
plate
place
foilseal
plate
thermal
cycler
run
protocol
describ
step
place
tpe
top
seal
plate
use
thermal
cycler
without
adjust
lid
ensur
thermal
cycler
preheat
wait
cycl
complet
prepar
magpix
instrument
refer
instrument
prepar
data
acquisit
cycl
program
complet
remov
seal
transfer
foilseal
plate
directli
preheat
magpix
plate
read
magpix
instrument
immedi
end
cycl
note
refer
magpix
softwar
user
manual
inform
refer
initi
instrument
setup
section
product
insert
first
time
instrument
use
nxtag
rpp
batch
exist
protocol
choos
nxtag
rpp
ta
protocol
batch
click
next
run
order
creat
synct
softwar
batch
name
run
name
creat
synct
softwar
select
appropri
well
sampl
analyz
click
unknown
select
well
highlight
import
sampl
list
click
import
list
enter
appropri
sampl
id
well
dilut
left
default
order
creat
synct
softwar
ensur
sampl
control
id
enter
match
id
use
creat
order
synct
softwar
synct
softwar
also
provid
option
export
sampl
control
id
import
xponent
import
list
function
sampl
id
name
duplic
within
run
sampl
must
uniqu
id
run
replic
run
control
sampl
pleas
make
sure
assign
uniqu
sampl
id
replic
click
save
batch
save
pend
batch
readi
run
clinic
perform
nxtag
rpp
assay
evalu
multicent
studi
conduct
four
clinic
site
north
america
nasopharyng
swab
specimen
pediatr
adult
subject
hospit
admit
hospit
emerg
depart
visit
outpati
clinic
resid
longterm
care
facil
exhibit
clinic
sign
symptom
respiratori
tract
infect
elig
inclus
prospect
studi
total
clinic
specimen
met
studi
inclus
criteria
prospect
collect
pediatr
adult
subject
suspect
respiratori
tract
infect
collect
januari
april
remain
enrol
januari
march
tabl
provid
summari
gener
demograph
inform
prospect
collect
nasopharyng
swab
includ
prospect
data
analysi
among
specimen
test
compar
assay
xtag
rvp
bidirect
sequenc
infect
rhinoviru
posit
influenza
posit
rsv
b
posit
hmpv
n
posit
influenza
b
n
preval
adenoviru
coronavirus
cov
cov
cov
cov
parainfluenza
virus
human
bocaviru
hbov
studi
popul
rang
major
hbov
adenoviru
rhinovirusenteroviru
cov
rsv
parainfluenza
virus
hmpv
infect
report
pediatr
subject
respiratori
virus
includ
influenza
gener
evenli
distribut
age
group
influenza
posit
specimen
type
influenza
c
pneumonia
pneumonia
repres
infect
prospect
studi
prospect
specimen
gener
valid
nxtag
rpp
result
analyt
first
attempt
invalid
result
gener
one
analyt
specimen
test
invalid
result
primarili
due
extern
control
failur
nonspecif
signal
extern
control
invalid
caus
invalid
result
includ
low
bead
count
intern
control
failur
inconclus
result
due
abnorm
signal
frequenc
invalid
result
evenli
distribut
among
clinic
site
avail
residu
specimen
rerun
nxtag
rpp
gener
valid
result
upon
retest
specimen
identifi
posit
refer
method
neg
nxtag
rpp
ie
rpp
fals
neg
confirm
neg
ie
refer
fals
posit
either
fdaclear
rtpcr
assay
routin
use
clinic
site
biofir
filmarray
rp
xtag
rvp
bidirect
sequenc
use
analyt
valid
primer
target
genom
region
distinct
target
nxtag
rpp
refer
fals
posit
specimen
includ
influenza
subtyp
influenza
influenza
b
hmpv
rhinoviru
tabl
show
resolv
perform
valu
follow
discrep
analysi
nxtag
rpp
detect
total
mix
infect
prospect
clinic
evalu
repres
nxtag
rpp
posit
specimen
studi
period
dual
infect
tripl
infect
posit
four
target
posit
five
target
respiratori
pathogen
probe
nxtag
rpp
except
c
pneumonia
implic
coinfect
preval
viru
involv
mix
infect
enterovirusrhinoviru
fig
retrospect
evalu
includ
total
uniqu
preselect
anonym
remnant
nasopharyng
swab
specimen
pediatr
adult
subject
confirm
infect
influenza
subtyp
adenoviru
parainfluenza
coronavirus
c
pneumonia
pneumonia
enteroviru
nxtag
rpp
accur
detect
viral
bacteri
pathogen
present
clinic
specimen
test
tabl
due
limit
number
sampl
posit
atyp
bacteri
pathogen
contriv
sampl
prepar
spike
vari
clinicallyrelev
concentr
six
strain
c
pneumonia
copiesml
six
strain
pneumonia
copiesml
neg
clinic
specimen
fifti
contriv
specimen
two
atyp
bacteria
prepar
test
along
neg
clinic
specimen
random
blind
fashion
test
site
nxtag
rpp
abl
detect
concentr
c
pneumonia
pneumonia
contriv
specimen
ci
limit
detect
lod
nxtag
rpp
target
assess
analyz
serial
dilut
simul
sampl
made
hightit
pathogen
stock
commerci
supplier
clinic
specimen
target
pathogen
commerci
avail
sampl
dilut
prepar
use
univers
transport
medium
utm
lod
titer
target
defin
lowest
concentr
sampl
test
gener
posit
call
lod
concentr
vari
target
major
rang
three
stock
sampl
provid
altern
unit
measur
determin
follow
lod
copiesml
hbov
copiesml
cov
ccuml
color
chang
unit
potenti
crossreact
assay
assess
use
pathogen
caus
respiratori
infect
probe
assay
pathogen
may
found
respiratori
specimen
well
pathogen
assay
design
detect
crossreact
evalu
simul
specimen
prepar
spike
cultur
organ
utm
viral
bacteri
target
prepar
cfuml
respect
highest
concentr
possibl
base
organ
stock
concentr
three
replic
pathogen
extract
analyz
nxtag
rpp
total
pathogen
test
target
plu
addit
strain
influenza
probe
assay
none
pathogen
includ
studi
found
crossreact
except
three
strain
nonpandem
influenza
solomon
data
shown
strain
crossreact
cov
titer
influenza
base
laboratori
test
silico
predict
high
titer
three
nonpandem
influenza
strain
may
result
fals
posit
call
cov
base
silico
analysi
also
potenti
presenc
cov
may
caus
fals
posit
influenza
call
presenc
may
caus
fals
posit
influenza
call
nevertheless
fals
posit
call
observ
target
either
prospect
preselect
sampl
set
clinic
studi
laboratori
test
supplement
silico
data
predict
rule
use
predict
reactiv
crossreact
specif
strain
genbank
sequenc
avian
human
swine
influenza
strain
adenoviru
serotyp
human
polioviru
strain
sar
cov
align
primer
sequenc
nxtag
rpp
reactiv
crossreact
predict
base
thermodynam
analysi
mismatch
primer
genom
sequenc
except
one
influenza
swine
strain
aswineeast
strain
analyz
predict
react
correct
primer
show
crossreact
analyt
primer
assay
swine
strain
expect
react
influenza
primer
primer
assay
accuraci
nxtag
rpp
determin
test
analyt
presenc
potenti
interf
substanc
organ
probe
assay
competit
interfer
due
pathogen
probe
nxtag
rpp
also
evalu
assess
effect
clinic
relev
coinfect
may
assay
nxtag
rpp
assay
abl
success
detect
analyt
concentr
three
time
lod
lod
presenc
potenti
interf
substanc
organ
data
shown
although
flumist
interfer
assay
abil
identifi
analyt
nxtag
rpp
abl
recogn
make
posit
call
attenu
virus
present
flumist
vaccin
expect
ie
influenza
influenza
influenza
influenza
b
addit
interfer
seen
analyt
part
nxtag
rpp
evalu
competit
interfer
one
pathogen
present
high
titer
second
pathogen
low
titer
lod
repeat
assess
nxtag
rpp
target
use
multianalyt
sampl
compris
two
four
analyt
prepar
spike
cultur
organ
utm
nasopharyng
swab
collect
anonym
asymptomat
volunt
use
neg
sampl
spike
sampl
assess
two
concentr
low
posit
lod
lod
moder
posit
lod
sampl
set
test
replic
start
sampl
extract
assess
singl
run
oper
use
set
instrument
strain
test
replic
detect
low
posit
moder
posit
concentr
neg
sampl
neg
target
reproduc
studi
perform
assess
total
variabl
nxtag
rpp
assay
across
oper
studi
site
test
day
instrument
assay
evalu
two
oper
three
site
test
reproduc
panel
triplic
nonconsecut
day
total
batch
run
oper
day
site
reproduc
panel
compris
one
neg
sampl
low
posit
multianalyt
sampl
lod
medium
posit
multianalyt
sampl
lod
prepar
utm
member
panel
total
data
point
batch
run
replic
per
batch
run
gener
agreement
expect
result
rang
per
analyt
overal
assess
potenti
carryov
crosscontamin
reaction
well
studi
conduct
use
neg
sampl
utm
altern
replic
high
titer
purifi
nucleic
acid
sampl
checkerboard
pattern
nxtag
rpp
plate
two
repres
viral
bacteri
pneumonia
analyt
examin
separ
run
high
titer
purifi
viral
nucleic
acid
sampl
ccuml
pneumonia
prepar
utm
order
obtain
posit
call
time
maxim
potenti
crosscontamin
carryov
crosscontamin
observ
nxtag
newest
innov
univers
tag
sort
chemistri
luminex
basi
nxtag
rpp
assay
technolog
retain
advantag
luminex
xtag
univers
array
technolog
provid
sever
enhanc
predecessor
xtag
technolog
nxtag
allow
scalabl
test
make
amen
lowand
highthroughput
applic
provid
flexibl
routin
daili
test
low
specimen
volum
also
abil
handl
unpredict
increas
sampl
volum
may
occur
key
advanc
nxtag
technolog
includ
significantli
reduc
handsontim
min
sampl
reduc
overal
turnaround
time
approxim
h
per
batch
includ
extract
notabl
conveni
rtpcr
bead
hybrid
reagent
lyophil
preplat
individu
well
allow
step
assay
process
postextract
carri
singl
close
tube
maxim
easeofus
minim
risk
crosscontamin
addit
accommod
larg
sampl
volum
would
possibl
user
autom
semiautom
postextract
step
use
standard
autom
plate
handler
pipet
robot
manual
setup
use
plate
format
extract
sampl
multichannel
pipettor
allow
entir
nxtag
plate
set
less
min
new
assay
chemistri
also
leverag
new
updat
primer
design
assay
target
addit
workflow
enhanc
present
clinic
perform
compar
origin
xtag
rvp
assay
sensit
specif
pathogen
except
note
bacteri
pathogen
sensit
valu
deriv
posit
specimen
rang
two
target
exhibit
posit
agreement
preselect
sampl
set
respect
data
gener
preselect
posit
specimen
particular
strength
multiplex
panel
nxtag
rpp
abil
detect
coinfect
studi
coinfect
seen
clinic
sampl
mani
caus
organ
treat
similarli
abil
accur
detect
organ
present
like
pathogen
import
confront
sever
organ
sampl
vari
risk
patient
furthermor
abil
detect
coinfect
import
organ
treat
influenza
rsv
adenoviru
pneumonia
infect
control
measur
appli
patient
popul
predominantli
immunocompromis
analyt
perform
also
similar
somewhat
better
preced
xtag
xtag
fast
assay
lod
rang
compar
lod
previou
assay
previous
publish
studi
report
perform
nxtag
rpp
compar
multiplex
molecular
respiratori
panel
studi
demonstr
excel
perform
nxtag
rpp
assay
confirm
diagnost
accuraci
compar
commerci
avail
multiplex
molecular
panel
varieti
assay
chemistri
well
inhous
develop
test
sever
studi
summar
beckmann
hirsch
compar
nxtag
rpp
multiplex
ligat
assay
parallel
respiratori
specimen
concord
result
obtain
sampl
concord
posit
concord
neg
nxtag
rpp
identifi
coinfect
vs
viral
pathogen
overal
addit
posit
result
involv
dual
rhinovirusrsv
infect
discord
sampl
retest
quantit
pcr
show
nxtag
rpp
neg
sampl
mainli
due
low
pathogen
level
suggest
higher
sensit
nxtagrpp
also
detect
multipl
infect
handson
time
extract
less
nxtag
rpp
vs
h
total
turnaround
time
vs
h
chen
cowork
evalu
perform
nxtag
rpp
comparison
filmarray
respiratori
panel
farp
singleplex
realtim
pcr
refer
nxtag
rpp
demonstr
overal
diagnost
sensit
specif
respect
influenza
also
detect
influenza
viru
matrix
gene
target
influenza
subtyp
gene
target
panel
remain
neg
complet
concord
nxtagrpp
farp
observ
posit
sampl
substanti
agreement
observ
target
author
conclud
good
diagnost
perform
high
sampl
throughput
reason
turnaround
time
nxtag
rpp
suitabl
multiplex
platform
routin
screen
respiratori
specimen
hospitalbas
laboratori
similarli
tang
et
al
evalu
nxtag
rpp
use
clinic
respiratori
specimen
previous
test
farp
assay
clinic
sensit
specif
rang
respect
agreement
influenza
genotyp
suggest
scalabl
reaction
batch
make
assay
potenti
solut
highthroughput
test
need
burdensom
nosocomi
outbreak
influenza
season
pandem
broton
et
al
compar
diagnost
accuraci
nxtag
rpp
anyplex
ii
assay
prospect
collect
nasopharyng
aspir
total
specimen
yield
concord
result
posit
percent
agreement
valu
rang
neg
percent
agreement
target
except
enterovirusrhinoviru
addit
nxtag
rpp
detect
singl
bacteri
mix
viralbacteri
infect
seven
sampl
sail
colleagu
evalu
nxtag
rpp
comparison
inhous
laboratori
develop
multiplex
realtim
pcr
panel
clinic
sampl
overal
agreement
assay
high
indic
kappa
coeffici
rang
hmpv
rsv
agreement
rhinovirusenteroviru
influenza
influenza
b
rsv
b
high
sampl
throughput
low
handson
time
make
nxtag
rpp
suitabl
screen
clinic
sampl
respiratori
pathogen
nxtag
respiratori
pathogen
panel
newest
gener
beadbas
multiplex
respiratori
pathogen
detect
avail
luminex
base
nxtag
chemistri
provid
sever
advantag
previou
xtag
univers
array
chemistri
reaction
compon
provid
lyophil
preplat
individu
seal
reaction
well
extract
nucleic
acid
sampl
ad
well
reseal
handson
manipul
workflow
maxim
easeofus
minim
risk
crosscontamin
describ
protocol
setup
reaction
process
thermal
cycler
read
magpix
analyz
prospect
multicent
studi
sever
publish
studi
describ
herein
demonstr
high
accuraci
nxtag
rpp
compar
xtag
predecessor
multiplex
assay
combin
simplifi
workflow
low
handsontim
scalabl
throughput
meet
need
varieti
laboratori
set
